Tuberin Regulates Prostaglandin Receptor-Mediated Viability, via Rheb, in mTORC1-Hyperactive Cells

In this study, we identify upregulation of EP3 (PTGER3) expression in TSC2-deficient cells, TSC renal angiomyolipomas, lymphangioleiomyomatosis lung nodules, and epileptic brain tubers. TSC2 negatively regulated EP3 expression via Rheb in a rapamycin-insensitive manner. The EP3 antagonist, L-798106, selectively suppressed the viability of TSC2-deficient cells in vitro and decreased the lung colonization of TSC2-deficient cells. Collectively, these data reveal a novel function of TSC2 and Rheb in the regulation of EP3 expression and cell viability. Implications: Therapeutic targeting of an aberrant PGE2-EP3 signaling axis may have therapeutic benefit for TSC patients and for other mTOR-hyperactive neoplasms. Mol Cancer Res; 15(10); 1318–30. ©2017 AACR.
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Tags: Cell Death and Survival Source Type: research

Related Links:

Publication date: Available online 17 January 2020Source: Molecular Aspects of MedicineAuthor(s): Rita Lampignano, Vera Kloten, Thomas Krahn, Thomas SchlangeAbstractLiquid biopsy holds great promise to complement traditional analysis on cancerous tissue during clinical management of cancer: screening of patients, (early) disease diagnosis, prognosis, therapy selection as well as early response to treatment and disease monitoring. Among emerging circulating biomarkers, cell-free miRNA (cfmiRNA) may have potential in detecting lung cancer and following the course of the disease. Furthermore, several studies highlighted the p...
Source: Molecular Aspects of Medicine - Category: Molecular Biology Source Type: research
Publication date: Available online 18 January 2020Source: Biochimica et Biophysica Acta (BBA) - Molecular Basis of DiseaseAuthor(s): Tomasz Kowalczyk, Michal Ciborowski, Joanna Kisluk, Adam Kretowski, Coral BarbasAbstractPrecision medicine (PM) means the customization of healthcare with decisions and practices adjusted to the individual patient. It includes personalized diagnostics, patients' sub-classification, individual treatment selection and the monitoring of its effectiveness. Currently, in oncology, PM is based on the molecular and cellular features of a tumor, its microenvironment and the patient's genetics and lif...
Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease - Category: Molecular Biology Source Type: research
Publication date: Available online 18 January 2020Source: Life SciencesAuthor(s): Khalil Hajiasgharzadeh, Mohammad Hossein Somi, Behzad Mansoori, Vahid Khaze Shahgoli, Afshin Derakhshani, Ahad Mokhtarzadeh, Dariush Shanehbandi, Behzad BaradaranAbstractAimsIt has been demonstrated that reduced expression of alpha7 nicotinic acetylcholine receptor (α7nAChR) led to reduced chemotherapeutic drugs resistance in various cancer cells. However, whether small interfering RNA (siRNA) mediated knockdown of α7nAChR can reduce sorafenib (SOR) resistance in HCC cells remains to be determined.Materials and methodsThe effects ...
Source: Life Sciences - Category: Biology Source Type: research
Publication date: Available online 18 January 2020Source: Biochimica et Biophysica Acta (BBA) - General SubjectsAuthor(s): Yunpeng Wei, Huanhuan Lv, Atik Badshah Shaikh, Wei Han, Hongjie Hou, Zhihao Zhang, Shenghang Wang, Peng ShangAbstractBackgroundCancer is one of the major threats to human health and current cancer therapies have been unsuccessful in eradicating it. Ferroptosis is characterized by iron-dependence and lipid hydroperoxides accumulation, and its primary mechanism involves the suppression of system Xc−-GSH (glutathione)-GPX4 (glutathione peroxidase 4) axis. Co-incidentally, cancer cells are also metab...
Source: Biochimica et Biophysica Acta (BBA) General Subjects - Category: Biochemistry Source Type: research
ConclusionsProgrammed cell death ligand 1 checkpoint therapy may be effective for recurrence of triple-negative breast cancer in a patient with autosomal dominant polycystic kidney disease and tuberous sclerosis complex.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
(CNN) — The US Food and Drug Administration approved a cannabis-based drug for the first time, the agency said Monday. Epidiolex was recommended for approval by an advisory committee in April, and the agency had until this week to make a decision. The twice-daily oral solution is approved for use in patients 2 and older to treat two types of epileptic syndromes: Dravet syndrome, a rare genetic dysfunction of the brain that begins in the first year of life, and Lennox-Gastaut syndrome, a form of epilepsy with multiple types of seizures that begin in early childhood, usually between 3 and 5. “This is an important...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Cannabis Local TV Marijuana Source Type: news
AbstractThe mechanistic target of rapamycin (mTOR), a protein kinase, is a central regulator of mammalian metabolism and physiology. Protein mTOR complex 1 (mTORC1) functions as a major sensor for the nutrient, energy, and redox state of a cell and is activated by ras homolog enriched in brain (RHEB1), a GTP-binding protein. Increased activation of mTORC1 pathway has been associated with developmental abnormalities, certain form of epilepsy (tuberous sclerosis), and cancer. Clinically, those mTOR-related disorders are treated with the mTOR inhibitor rapamycin and its rapalogs. Because the effects of chronic interference wi...
Source: AGE - Category: Geriatrics Source Type: research
Tuberous sclerosis complex (TSC) is an autosomal dominant and multi-system genetic disorder in humans. TSC affects around 25,000 to 40,000 individuals in the United States and about 1 to 2 million individuals worldwide, with an estimated prevalence of one in 6,000 newborns. TSC occurs in all races and ethnic groups, and in both genders. TSC is caused by defects or mutations in two genes, TSC1 and TSC2. Loss of TSC1/TSC2 leads to dysregulation of mTOR, resulting in aberrant cell differentiation and development, and abnormal enlargement of cells. TSC is characterized by the development of benign and/or malignant tumors in se...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
(Cincinnati Children's Hospital Medical Center) In an international study, the drug everolimus has been shown to significantly reduce the frequency of seizures in patients with treatment-resistant epilepsy and tuberous sclerosis complex (TSC) -- a genetic disease that causes malformations and tumors in the brain and other vital organs.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Charlotte with Jurriaan Peters, MD, in the Clinical and Translational Study Unit. When Charlotte D’Amario was about 4½ months old, she began making odd, forward-lurching movements. At first, her pediatrician thought it was reflux—that she was trying to spit up. “It was getting worse and worse, and no one had a clue as to what it was,” says Allyson, her mother. Her parents started to videotape her while she made these odd motions. They occurred in clusters of as many as 50 at a time, several times a day. Seeing videos of Charlotte at 8½ months, her pediatrician sent her to a neurologist...
Source: Thrive, Children's Hospital Boston - Category: Pediatrics Authors: Tags: All posts Diseases & conditions Our patients’ stories Research Tests & treatment epilepsy seizures TSC tuberous sclerosis complex Source Type: news
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Cardiology | Clinical Trials | Epilepsy | Heart | Neurology | Skin | Study | Toxicology | Tuberous Sclerosis | Urology & Nephrology